Interferon News and Research

RSS

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New data on four Bristol-Myers Squibb Company (NYSE:BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

3 Oct 2009

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Bristol-Myers Squibb Company and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston.

3 Oct 2009

Phase 2 clinical trial results of IMO-2055 announced

Idera Pharmaceuticals, Inc., today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The data are being presented during the Eighth International Kidney Cancer Symposium being held in Chicago, September 25-26, 2009.

28 Sep 2009

Researchers study functional similarity between zebrafish and humans to fight infections

Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms. Zebrafish are becoming an important model for human disease, since they are easily handled, maintained and manipulated and many fundamental processes between zebrafish and humans are conserved.

24 Sep 2009

Genetic variation helps identify hepatitis C infected people, according to a study

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

24 Sep 2009

Increasing the half life of proteins to treat diseases such as hepatitis B

Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body. The TUM spin-off XL-Protein GmbH has now started to further develop this new technology with blockbuster potential.

21 Sep 2009

New interferon/lovastatin treatment to battle cancer

For selected patients, he decided he might have something better. He now has opened NeoPlas Innovation in Nashville to offer the combination "off-label" treatment on an outpatient basis.

21 Sep 2009

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

17 Sep 2009

Nebulized interferon-gamma helps minimize transmissibility of TB

A new study published in the September 15, 2009, issue of PLoS ONE found that patients with cavitary pulmonary tuberculosis receiving anti-TB medications supplemented with nebulized interferon-gamma have fewer bacilli in the lungs and less inflammation, thereby reducing the transmissibility of tuberculosis in the early phase of treatment.

15 Sep 2009

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced data presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) showing the potential of TYSABRI® (natalizumab) to redefine successful multiple sclerosis (MS) therapy.

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

AVONEX results in fewer injection site reactions, according to a clinical study

Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon- (interferon beta-1b), Copaxone- (glatiramer Acetate) or Rebif - (interferon beta-1a).

13 Sep 2009

New treatment strategies for multiple sclerosis

The drawback in the new immunotherapies in multiple sclerosis (MS) includMe severe infections that can be fatal. For example, treatment with natalizumab, which reduces the immune surveillance of the brain, can lead to the development of progressive multifocal leukoencephalopathy (PML), a typically fatal form of viral encephalitis.

10 Sep 2009

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

Interferon News and Research

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Vivaldi receives US patent for live attenuated influenza vaccines

Schering-Plough receives FDA recommendation approval for PEGINTRON

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

Phase 1b clinical trial results of PEG-Interferon lambda to be presented

Phase 2 clinical trial results of IMO-2055 announced

Researchers study functional similarity between zebrafish and humans to fight infections

Genetic variation helps identify hepatitis C infected people, according to a study

Increasing the half life of proteins to treat diseases such as hepatitis B

New interferon/lovastatin treatment to battle cancer

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

Nebulized interferon-gamma helps minimize transmissibility of TB

Data from Phase III clinical trial of TYSABRI presented at ECTRIMS

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

AVONEX results in fewer injection site reactions, according to a clinical study

New treatment strategies for multiple sclerosis

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News